Contrast Use In Artificial Urinary Sphincter Does Not Affect Device Survival
- byDoctor News Daily Team
- 19 July, 2025
- 0 Comments
- 0 Mins
Prostate cancer survivors have incontinence rates of 4% to 87% for one year after prostatectomy. The artificial urinary sphincter (AUS) remains the gold standard for post-prostatectomy incontinence. In a study, researchers have reported that the use of contrast in the AUS does not appear to change rates of device malfunction, fluid loss, or need for reoperation. The research has been published in the journal Neurology and Urodynamics on April 03, 2021.
AUS can be filled with normal saline (NS) or isotonic contrast solution. However, surgeons have voiced concerns about the impact on device malfunction and longevity, but no studies address this issue. Therefore, researchers of the Duke University Medical Center, USA, conducted a study to identify differences in outcomes between NS and contrast-filled AUS.
For this analysis, the researchers included a total of 39,363 patients in the industry who maintained the AUS database (Boston Scientific) from 2001 to 2016. They divided the patients into two groups: AUS filled with NS or contrast. They compared the patient demographics and device characteristics. The device survival was determined as time to the need for reoperation. They also compared device survival between AUS filled with NS versus contrast using a Kaplan–Meier curve adjusted for age, cuff size, and pressure regulating balloon (PRB) size.
Key findings of the study were:
Among 39,363 patients, 34,674 (88.1%) devices were filled with NS.
The researchers noted that the overall reoperation rate was 24.5%, with no difference between groups with a mean time to the operation of 3 years.
After adjustment for age, cuff size, and PRB size using Kaplan–Meier analysis, they found a similar time to reoperation between the two groups.
The authors concluded, "The use of contrast in the AUS does not appear to change rates of the device malfunction, fluid loss, or need for reoperation. Since filling the device with contrast does not appear inferior to saline in terms of longevity, we feel this should be considered a safe tool for the implanting surgeon."
For further information:
https://onlinelibrary.wiley.com/doi/10.1002/nau.24668
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Eli Lilly plans to build new USD 3 billion facilit...
- 04 November, 2025
Rajkot Maternity Hospital CCTV Leak: How a simple...
- 04 November, 2025
Gland Pharma profit rises 12 percent to Rs 184 cro...
- 04 November, 2025
AIIMS Delhi doctors told to use Hindi in prescript...
- 04 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!